Magnetic field assisted α-Fe2O3/Zn1-xFexO heterojunctions for accelerating antiviral agents degradation under visible-light

Reducing the recombination efficiency of photo-induced carriers has been found as an effective means to improve the degradation of antiviral agents. Given that the Lorentz forces can cause the abnormal charge to move in the opposite direction, external magnetic field improved alpha-Fe2O3/Zn1-xFexO heterojunctions (FZHx) were developed to remove increasing antiviral agents that were attributed to the COVID-19 pandemic under visible light. The characterization of the mentioned FZHx in the external magnetic field indicated that FZHx had perfect photocatalytic activity for degrading antiviral agents. In the external magnetic field, the quantities of photo-generated carriers and free radicals (center dot OH and center dot O-2(-)) derived from FZHx increased significantly, which improved antiviral agent removal by 30.0%. Though the band structure (alpha-Fe2O3) is unlikely to change due to some orders of magnitude weaker of Zeeman energy in magnetic fields, which insignificantly impacts photocatalytic performance. However, this study proposed a strategy of negative magnetoresistance effects and heterojunctions to facilitate the separation and transfer of photo-induced carriers in magnetic fields. Based on the proposed strategy, spin oriented electrons were selected and accumulated on the conduction band, which contributed to the degradation of antiviral agents. Overall, this study presented novel insights into the improved degradation performance of antiviral agents by applying Fe-based heterojunctions in an external magnetic field.

Automated summary

This study improved the degradation performance of antiviral agents by applying Fe-based heterojunctions in an external magnetic field, increasing the removal efficiency by 30.0%. The strategy of negative magnetoresistance effects and heterojunctions facilitated the separation and transfer of photo-induced carriers in magnetic fields, contributing to the degradation of antiviral agents.